重组抗人CD47单抗(B6H12)流式 | Syd Labs PA007470.h1Fs
重组抗人CD47单克隆抗体(克隆号B6H12) ，人IgG1 Fc Silent Kappa(Syd Labs货号：PA007470.h1Fs)是用哺乳动物细胞生产的重组抗体，可用于流式细胞术和免疫组织化学-冷冻等研究，纯度>95%。其不变区为人Human IgG1 Kappa (hIgG1或h1)，可与重组人IgG1同型对照抗体配套使用。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。
产品参数
| 货号 | PA007470.h1Fs |
|---|---|
| 产品名称 | 重组抗人CD47单抗(B6H12)流式 | Syd Labs PA007470.h1Fs |
| 英文名 | Recombinant Anti-human CD47 Monoclonal Antibody (Clone: B6H12), Human IgG1 Fc Silent Kappa |
| 供货商名称 | Syd Labs, Inc. |
| 品牌名 | Syd Labs |
| 别称 | CD47，CD47 抗原，CD47 分子，CD47 糖蛋白，整合素相关蛋白，整合素相关蛋白，白细胞表面抗原 CD47，MER6，蛋白 MER6，Rh 相关抗原，OA3，IAP |
| 概述 | Syd Labs提供重组人IgG1同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 克隆号 | B6H12 |
| 同种型 | 人 IgG1 kappa |
| 特异性 | 该重组 B6H12 抗体与人 CD47 蛋白特异性结合 |
| 免疫源 | 重组抗人CD47单克隆抗体 (克隆：B6H12)在哺乳动物细胞中产生 |
| 抗体形式 | 0.2微米过滤溶液，pH 7.4，含0.09%叠氮化钠 |
| 偶联 | 非偶联 |
| 纯度 | >95%（在还原条件下通过SDS-PAGE测定） |
| 运输 | 重组抗人CD47单克隆抗体(克隆号B6H12) ，人IgG1 Fc Silent Kappa用冰袋运输。收到后，请立即将其存放在下面建议的温度下。 |
| 稳定性与存储 | 使用手动除霜冰箱并避免重复冻融循环。 自收到之日起 12个月，保存在2 至 8°C。 请勿冻结。 |
| 注意事项 | PA007470.h1Fs Syd Labs提供重组人IgG1同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 产品咨询 | Syd Labs在国内只通过代理商销售其产品，不做直销。终端用户咨询价格请联系Syd Labs中国代理商。 关于Syd Labs产品如果有任何技术或其它问题，欢迎随时联系Syd Labs国内市场推广合作伙伴：武汉多找找科技有限公司，企业微信：duozhaozhao2024 联系电话：18162581039（龙经理） |
| 应用详情 | 流式细胞术（FC）和免疫组织化学-冷冻（IHC-F）。 |
文献
重组抗人CD47单克隆抗体(克隆号B6H12) ，人IgG1 Fc Silent Kappa（Recombinant Anti-human CD47 Monoclonal Antibody (Clone: B6H12), Human IgG1 Fc Silent Kappa，货号：PA007470.h1Fs Syd Labs）
CD47是一种广泛表达于免疫细胞、造血细胞及多种肿瘤细胞表面的五次跨膜糖蛋白，通过与巨噬细胞表面的信号调节蛋白α（SIRPα）特异性结合，传递“别吃我”（Don’t eat me）抑制性信号，帮助细胞逃避巨噬细胞的吞噬作用。经典克隆号B6H12单克隆抗体能够特异性识别CD47胞外域的构象表位，有效阻断CD47与SIRPα之间的相互作用，解除巨噬细胞的吞噬抑制。抗人CD47单抗（B6H12抗体）被广泛应用于多色流式细胞术表达检测、体外巨噬细胞吞噬实验（ADCP）、细胞粘附与迁移阻断，以及肿瘤免疫逃逸机制和靶向免疫治疗的前沿研究。
Syd Labs推出的重组抗人CD47单抗（B6H12抗体）采用先进的哺乳动物表达系统重组合成，克服了传统杂交瘤表达中的批间不稳定与抗体漂移，确保了极高一致性的结合活性与高纯度。该产品按体内实验级（In Vivo Grade）标准严格精制，具备极低内毒素（Low Endotoxin）水平且无防腐剂成分，有效避免了在敏感细胞培养及体内动物实验中的细胞毒性干扰。采用标准的Mouse IgG1 Kappa结构，Syd Labs B6H12抗体与配套同型对照结合使用，能够为免疫学、肿瘤学及生物医药研发提供科学严谨、高重复性的实验数据保障。
抗人CD3e单抗（OKT3）部分参考文献:
1. Mass spectrometric profiling of HLA-B44 peptidomes provides evidence for tapasin-mediated tryptophan editing
Kaur, A., et al. J Immunol. 2023. doi: 10.4049/jimmunol.2300405
“This study uses mass spectrometry to explore tapasin-mediated tryptophan editing in HLA-B44 peptidomes. The W6/32 antibody (anti-human HLA-ABC) was purified from mouse ascites and crosslinked to PureProteome Protein A magnetic beads for immunoaffinity purification. Cells were stained with W6/32-FITC antibody for surface HLA class I analysis via quantitative flow cytometry, revealing a significant reduction in HLA-B44:05 molecules on tapasin knockout cells compared to wild-type cells. A slight, non-significant decrease in HLA-B44:05 surface stability was observed in tapasin knockout cells in the presence of brefeldin A.”
2. Inhibition of major histocompatibility complex-I antigen presentation by sarbecovirus ORF7a proteins
Zhang, F., et al. Proc Natl Acad Sci U S A. 2022. doi: 10.1073/pnas.2208191119
“This study investigates how sarbecovirus ORF7a proteins inhibit MHC-I antigen presentation. Human 293T, HuH7.5, U2OS, and A549/ACE2 cells were transduced with lentiviral vectors expressing SARS-CoV-2 ORF7a or Nef and stained with the pan-HLA-ABC antibody W6/32 for flow cytometry. MHC-I surface levels, measured by median fluorescence intensity, were reduced in ORF7a-expressing cells. The study compared wild-type and ORF7-deleted SARS-CoV-2 strains, confirming ORF7a’s role in suppressing MHC-I expression.”
3. Assessments of HLA-I Specificities of Anti-HLA-I Monoclonal Antibodies Using Solid Phase Bead Arrays
Zaitouna, A. J., et al. Bio Protoc. 2020. doi: 10.21769/BioProtoc.3862
“This study evaluates anti-HLA-I monoclonal antibody specificities using solid phase bead arrays. The W6/32 antibody, a pan anti-HLA class I antibody, was used to normalize HLA-I protein levels on Labscreen and FlowPRA Single Antigen Beads. Biotinylated W6/32 was tested at various dilutions (undiluted to 1:100) alongside anti-Bw4 and anti-Bw6 antibodies. Representative data showed W6/32 binding to HLA-I beads, with isotype control IgG2a used for comparison.”
4. Strategies for the measurements of expression levels and half-lives of HLA class I allotypes
Raghavan, M., et al. Hum Immunol. 2019. doi: 10.1016/j.humimm.2019.01.011
“This study describes methods for measuring HLA class I expression and half-lives using the W6/32 antibody (anti-human HLA-ABC). Flow cytometry histograms showed W6/32 signals for monocytes, NK cells, B cells, CD8+ T cells, and CD4+ T cells, with geometric mean values quantifying HLA class I expression. The W6/32 antibody was chosen for its broad recognition of most HLA class I allotypes, facilitating consistent assessment across healthy donors.”
5. Higher human lymphocyte antigen class I expression in early-stage cancer cells leads to high sensitivity for cytotoxic T lymphocytes
Akazawa, Y., et al. Cancer Sci. 2019. doi: 10.1111/cas.14022
“This study examines HLA class I expression in early-stage hepatocellular carcinoma (HCC) using the W6/32 antibody (anti-human HLA-ABC). Flow cytometry analysis of tissue from five HCC patients compared HLA class I expression between cancer cells and non-tumorous hepatocytes. The mean fluorescence intensity ratio of W6/32 staining indicated higher HLA class I expression in cancer cells, enhancing sensitivity to cytotoxic T lymphocytes. Heterogeneous expression was observed in non-tumorous hepatocytes in one case.”